ICMR Director-General Balram Bhargava says “Regarding the study on re-infection study, we are taking the cut off of 100 days, it is still in progress.”
The details of the study were not explained.
Dr. Bhargava adds “The virus drifts will not determine the effectiveness of the vaccines being developed. Major changes in the virus can take place in a decade or two.”
NITI Aayog member (Health) says “The two indigenous vaccines are at final stage of the phase-II of the clinical trial, the results will be out soon, on the basis of which further strategy will be devised. The third vaccine candidate (Oxford) involving Serum Institute, is undergoing the third-phase clinical trial. Results are expected in November end or so.” – The Hindu